Glaucoma is the leading cause of blindness in the United States accounting for 9-12% of all cases of blindness. Currently, the front line treatment for glaucoma are prostaglandins that may have to be taken up to several times a day. Even with proper treatment, roughly 11% of the patients using the treatment are non-compliant and lose their vision. In this project, ForSight Laboratories has developed a pharmaceutical drug delivering implant with the capability of sustaining long-term release of a prostaglandin as a new way to treat the condition. This project reports the product development of a polymer drug matrix with a controlled release in order to better treat glaucoma. Accompanying product development, a mathematical model was created in order to strengthen the understanding of the dosage profile and to predict long term dosages.
","abstract_html":"<p>Glaucoma is the leading cause of blindness in the United States accounting for 9-12% of all cases of blindness. Currently, the front line treatment for glaucoma are prostaglandins that may have to be taken up to several times a day. Even with proper treatment, roughly 11% of the patients using the treatment are non-compliant and lose their vision. In this project, ForSight Laboratories has developed a pharmaceutical drug delivering implant with the capability of sustaining long-term release of a prostaglandin as a new way to treat the condition. This project reports the product development of a polymer drug matrix with a controlled release in order to better treat glaucoma. Accompanying product development, a mathematical model was created in order to strengthen the understanding of the dosage profile and to predict long term dosages.</p>","abstract_has_math":false,"creators":["Tsoi, Eric W."],"institution":null,"degree_name":"MS in Polymers and Coatings","degree_level":null,"degree_discipline":"Chemistry & Biochemistry","degree_department":null,"school":null,"contributors":["Raymond Fernando"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-12-01T08:00:00Z","date_published":"2013-12-01T08:00:00Z","updated_at":"2026-07-24T01:31:28Z","subjects":["Formulation","Polymer","Controlled Release","Glaucoma","Biomedical Devices and Instrumentation","Pharmaceutical Preparations","Polymer Chemistry"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["10.15368/theses.2013.214"],"render_values":[{"text":"10.15368/theses.2013.214","href":"https://doi.org/10.15368/theses.2013.214","code":true}]}]},"links":{"outbound_url":"https://digitalcommons.calpoly.edu/theses/1134","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Raymond Fernando"]},{"key":"dc:creator","label":"Author","values":["Tsoi, Eric W."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2017-01-20T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry & Biochemistry"]},{"key":"thesis:degree_name","label":"Degree Name","values":["MS in Polymers and Coatings"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Formulation","Polymer","Controlled Release","Glaucoma","Biomedical Devices and Instrumentation","Pharmaceutical Preparations","Polymer Chemistry"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.calpoly.edu/theses/1134","10.15368/theses.2013.214"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Glaucoma is the leading cause of blindness in the United States accounting for 9-12% of all cases of blindness. Currently, the front line treatment for glaucoma are prostaglandins that may have to be taken up to several times a day. Even with proper treatment, roughly 11% of the patients using the treatment are non-compliant and lose their vision. In this project, ForSight Laboratories has developed a pharmaceutical drug delivering implant with the capability of sustaining long-term release of a prostaglandin as a new way to treat the condition. This project reports the product development of a polymer drug matrix with a controlled release in order to better treat glaucoma. Accompanying product development, a mathematical model was created in order to strengthen the understanding of the dosage profile and to predict long term dosages.
"]},{"key":"dc:title","label":"Title","values":["Formulation Development of a Polymer-Drug Matrix with a Controlled Release Profile for the Treatment of Glaucoma"]}]}],"canonical_facts":{"dc:contributor":["Raymond Fernando"],"dc:creator":["Tsoi, Eric W."],"dc:date.available":["2017-01-20T08:00:00Z"],"dc:description.abstract":["Glaucoma is the leading cause of blindness in the United States accounting for 9-12% of all cases of blindness. Currently, the front line treatment for glaucoma are prostaglandins that may have to be taken up to several times a day. Even with proper treatment, roughly 11% of the patients using the treatment are non-compliant and lose their vision. In this project, ForSight Laboratories has developed a pharmaceutical drug delivering implant with the capability of sustaining long-term release of a prostaglandin as a new way to treat the condition. This project reports the product development of a polymer drug matrix with a controlled release in order to better treat glaucoma. Accompanying product development, a mathematical model was created in order to strengthen the understanding of the dosage profile and to predict long term dosages.
"],"dc:identifier":["https://digitalcommons.calpoly.edu/theses/1134","10.15368/theses.2013.214"],"dc:subject":["Formulation","Polymer","Controlled Release","Glaucoma","Biomedical Devices and Instrumentation","Pharmaceutical Preparations","Polymer Chemistry"],"dc:title":["Formulation Development of a Polymer-Drug Matrix with a Controlled Release Profile for the Treatment of Glaucoma"],"thesis:degree_discipline":["Chemistry & Biochemistry"],"thesis:degree_name":["MS in Polymers and Coatings"]},"updated_at":"2026-07-24T01:31:28Z"}